Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Diabetes Care Publish Ahead of Print published online ahead of print March 17, 2008
DOI: 10.2337/dc07-2306
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-2306v1
31/6/1165    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Saraheimo, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Saraheimo, M.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes

M. Saraheimo, MD1,,2, C. Forsblom, MD, DMSC1,,2, L. Thorn, MD1,,2, J. Wadén, MD1,,2, M. Rosengård-Bärlund, MD1,,2, O. Heikkilä, MD1,,2, K. Hietala, MD1, D. Gordin, MD2, J. Frystyk, MD, DMSC, PHD3, A. Flyvbjerg, MD, DMSC3, P.-H. Groop, MD, DMSC on behalf of the FinnDiane Study Group1,,2

1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki
2Division of Nephrology, Department of Medicine, Helsinki University Central Hospital, Finland
3Medical Department M (Diabetes and Endocrinology) and the Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Denmark

per-henrik.groop{at}helsinki.fi

ABSTRACT

Objective: To elucidate whether serum adiponectin is associated with progression of diabetic nephropathy in type 1 diabetic patients.

Research Design And Methods: A prospective follow-up study, a part of the nationwide Finnish Diabetic Nephropathy Study. 1330 type 1 diabetic patients were followed for 5.0±2.2 years. Patients were divided at baseline into three groups according to their urinary albumin excretion rate (AER) in three consecutive overnight or 24 hour urine collections: 818 patients with normoalbuminuria [NA](AER < 20 ug/min), 216 with microalbuminuria [mi](20 ug/min < AER< 200ug/min) and 296 with macroalbuminuria [MA](AER > 200ug/min). Progression of albuminuria was the main outcome. Adiponectin was measured by a time-resolved immmunofluorometric assay, and the values were log-transformed and adjusted for age, BMI and sex before analysis.

Results: 193 patients progressed either to the next albuminuria level or end-stage renal disease (ESRD). No difference in adiponectin concentrations was observed between progressors and non-progressors in NA or MI patients. In the MA patients, progression to ESRD was associated with higher adiponectin in the entire group (23.4 ±17.1 vs. 16.0±8.5 mg/l, P<0.001) and in men (P<0.001) and women (P<0.001) separately. Progression to ESRD was also associated with systolic blood pressure (SBP), insulin dose, HbA1c, S-cholesterol, S-triglycerides, AER and estimated glomerular filtration rate (eGFR). When these covariates were inserted in a Cox regression analysis, HbA1c, triglycerides, eGFR and adiponectin were significantly associated with progression from macroalbuminuria.

Conclusions: Increased serum adiponectin levels predict the progression from macroalbuminuria to ESRD in type 1 diabetic patients.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2008 by the American Diabetes Association.